Syncom Formulations India Ltd

AGM details

• Date and time: 30 September 2026, 2:00 PM to 2:42 PM IST
• Mode: VC/OAVM; venue deemed the registered office
• Quorum: cut-off 23 September 2026; 73 attendees via VC/OAVM
• Remote and on-site e-voting available; results to be declared within two working days

Ordinary resolutions

• Adoption of standalone and consolidated financial statements for year ended March 31, 2026
• Dividend of ₹0.10 per equity share for FY2025-26
• Re-appointment of Ankit Kedarmal Bankda on retirement by rotation

Special resolutions

• Ratification of remuneration of Cost Auditor for FY 2026-27
• Confirmation of appointment of Rahul Vijay Bankda as Director
• Confirmation and approval of Rahul Vijay Bankda as Managing Director; remuneration approved
• Confirmation of appointment of Mrs. Rinki Ankit Bankda as Director
• Approval of remuneration payable to Mrs. Rinki Ankit Bankda as Whole-Time Director
• Approval to increase remuneration payable to CFO Ankur Vijay Bankda
• Re-appointment of Mrs. Ruchi Jindal as Woman Independent Director

Director changes

• Ankit Kedarmal Bankda re-appointed (retiring by rotation)
• Rahul Vijay Bankda appointed as Director and MD
• Rinki Ankit Bankda appointed as Director and Whole-Time Director; remuneration approved
• Ruchi Jindal re-appointed as Woman Independent Director

Auditor & governance

• Statutory Auditor: Sanjay Mehta & Associates; no change announced

Voting results

• Results of e-voting to be announced within two working days; Scrutinizer report to be obtained

Dividend waiver by Promoters/Promoter Group

• Promoters/promoter group voluntarily waive final dividend for FY ended 31 March 2026.
• Board recommended final dividend of ₹0.10 per equity share (face value ₹1).
• Total equity shares are 94,00,00,000; promoters hold 47,53,47,599.
• Waived amount: ₹4,75,34,759.90; net payable dividend: ₹4,64,65,240.10.
• Dividend payable to promoters/promoter group is nil, subject to AGM approval.
• Waiver is voluntary and unconditional; no consideration payable by the company.
• Intimation submitted to exchanges for information of members and stakeholders.

Record Date & Dividend Details

• Record Date: 23 September 2026 for entitlement.
• Dividend: 10% i.e. Rs 0.10 per equity share.
• Subject to shareholders' approval at the 38th AGM.

Dividend Waiver & AGM Timeline

• Dividend waiver form due by 26 September 2026.
• AGM to be held 30 September 2026 via VC/OAVM.

Filing context

• BRSR filing for FY2025-26 on standalone basis; XBRL filing planned.
• Submitted under Regulation 34(2)(f) of SEBI LODR.
• Documents to be hosted on the company website.

Financials & structure

• Turnover ₹48,657.28 lakh; net worth ₹40,624.59 lakh.
• Paid-up capital ₹94 crore; 94 crore shares of ₹1 each.
• Subsidiaries: Synmexpharma, Vincit Biotech, Sante Biotech; 100% owned.

ESG & operations highlights

• Total energy consumed: 65,68,586.4; electricity 11,76,680.4; non-renewables 53,91,906.
• Water withdrawal: 48,114 KL; water intensity 0.988 per ₹ lakh turnover.
• Waste: total waste generated 0.9 MT; landfilling 1.03 MT.
• Board size: 6 directors; 1 female (16.66%); KMP 2; 1 female (50%).

AGM details

• AGM on 30 September 2026 at 2:00 PM via VC/OAVM; venue deemed at the registered office.

AGM notice and AR access

• AGM scheduled for 30 September 2026 at 2:00 PM via VC/OAVM.
• FY2025-26 Annual Report and AGM notice available on company site and stock exchanges.

Non-registered email shareholder communications

• Letters dispatched to shareholders without registered emails containing AR access weblink.
• Sample letter enclosed; regulatory basis Regulation 36(1)(b) LODR cited.

Access to copies and updates

• Physical copies of Annual Report available on request via finance@sfil.in.
• Update email/address/details by contacting the Registrar Ankit Consultancy.

Financial snapshot

• Total Income (Standalone) ₹51,753.91 L; Revenue from Ops ₹48,657.28 L.
• Consolidated Total Income ₹52,051.14 L; PAT ₹7,283.07 L; PBT ₹10,111.95 L.
• Standalone EPS ₹0.81; Consolidated EPS ₹0.81; Dividend ₹0.10 per share proposed.
• Standalone CFO ₹5,829.20 L; Standalone Borrowings ₹68.13 L; Equity share capital ₹9,400 L.
• Cash and cash equivalents: Standalone ₹512.03 L; Consolidated ₹514.75 L.

Segment performance

• Pharmaceuticals: Revenue ₹51,274.35 L; segment PBT ₹9,865.61 L; assets ₹43,517.55 L.
• Trading: Revenue ₹110.03 L; segment PBT ₹-2.63 L.
• Renting: Revenue ₹369.53 L; segment PBT ₹300.01 L.
• Total segment result after finance cost ₹10,162.99 L; Pharma drives majority.

Capital structure & dividends

• Equity share capital ₹9,400 L; no change in capital structure.
• Final dividend proposed ₹0.10 per share; record date 23-Sep-2026; payout by 30-Oct-2026.
• AGM to be held 30-Sep-2026 via VC/OAVM.

Governance & leadership changes

• New MD: Rahul Vijay Bankda (DIN 00827827) appointed for 3 years from 12-Aug-2026.
• New Whole-Time Director: Mrs. Rinki Ankit Bankda from 12-Aug-2026.
• New CFO: Mr. Ankur Vijay Bankda from 12-Aug-2026.
• Aug 2025: Resignations of Kedarmal Bankda and Vijay Bankda; prior WTD and MD roles vacated.

CSR & ESG highlights

• CSR obligation ₹82.00 L; expenditure ₹82.50 L; excess ₹0.50 L; 2% avg net profit basis met.
• CSR activities: Education and Health; CSR policy hosted on website.
• Energy: Solar plant generated 9.60 L units; saved ₹55.38 L; 8.50 L consumed captive power.
• Waste: Total 0.9 MT; landfilling 1.03 MT; e-waste managed via authorized recyclers.
• Water: 48,114 KL withdrawn; intensity ₹0.988 per turnover; plant uses ETP/STP treated water.

Audit & governance

• Statutory Auditor: Sanjay Mehta & Associates; Secretarial Auditor: D.K. Jain & Co.
• Board met 6 times; Independent Directors met; Audit, NRC, CSR, RMC committees in place.
• Management and CFO certified compliance; Internal controls deemed adequate per auditor’s report.

Subsidiaries & consolidation

• Wholly owned subsidiaries: Sante Biotech Pvt Ltd, Synmex Pharma Pvt Ltd, Vincit Biotech International Pvt Ltd.
• Consolidated financial statements prepared under Ind AS; 3 subsidiaries included.

Outlook & risks

• Global pharma growth remains supportive; regulatory price controls and generic competition pose risk.
• Growing e-pharmacy and preventive healthcare opportunities in India; supply chain and input costs monitored.
• Company emphasizes disciplined execution, continuous leadership development, and sustainable value creation.

Q1 FY2026-27 financials

• Consolidated total income: ₹133.36 crore for Q1 FY2026-27, up 8% YoY.
• Profit before tax: ₹32.25 crore, up 59% YoY.
• Profit after tax: ₹24.85 crore, up ~58% YoY.
• Revenue from operations: ₹125.53 crore, up nearly 7%.
• Earnings per share: ₹0.26, up from ₹0.17.

Dividend and business outlook

• Board recommends final dividend ₹0.10 per equity share for FY ending 31 March 2026, subject to AGM.
• Dividend contingent on shareholder approval at ensuing AGM.
• Domestic business supported by 1,000+ medical representatives; exports to 15+ countries.
• Company emphasizes ethical prescription-led model and sustainable growth.